Physician profile
Daniel S Mccally
NPI 1710920830
$1,734.69
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $177 · 2021: $386 · 2022: $436 · 2023: $337 · 2024: $41.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.60 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $508.34 | 2019-2024 | Myrbetriq, Veozah |
| Neotract INC. | $259.91 | 2019-2020 | |
| Antares Pharma, INC. | $195.70 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Myovant Sciences INC. | $193.30 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $142.65 | 2023 | Orgovyx, Gemtesa |
| Coloplast Corp | $98.57 | 2019-2021 | |
| Urovant Sciences INC | $54.53 | 2022 | |
| Myriad Genetic Laboratories, INC. | $34.04 | 2022 | |
| Janssen Biotech, INC. | $28.79 | 2021 | |
| Halozyme INC | $28.41 | 2023 | |
| Endo Pharmaceuticals INC. | $22.05 | 2019 | |
| Blue Earth Diagnostics | $20.61 | 2022 | |
| Acerus Pharmaceuticals Corporation | $20.54 | 2022 | |
| Ferring Pharmaceuticals INC. | $20.11 | 2024 | Adstiladrin |
| Clarus Therapeutics INC. | $19.62 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.04 | 2022 | |
| Axonics, INC. | $18.97 | 2023 | Bulkamid |
| Travere Therapeutics, INC. | $17.73 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.42 | 2022 | |
| Tersera Therapeutics LLC | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mccally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.